Axon Therapies Secures $32 Million in Series A Funding for Heart Failure Innovations
Axon Therapies Secures $32 Million in Series A Funding for Heart Failure Innovations
On September 25, 2025, Axon Therapies, a clinical-stage medical device company, announced the successful completion of an oversubscribed Series A funding round, raising $32 million to transform heart failure treatment. This financing round was co-led by Earlybird Venture Capital and Santé Ventures, with contributions from existing investor Deerfield Management, as well as newcomers CD Capital and KOFA Healthcare.
Focus on Heart Failure Treatment
Heart failure affects millions globally and poses significant challenges for those diagnosed due to a lack of effective treatment options. The funding will facilitate a series of clinical trials focused on a minimally invasive technique aimed at a fundamental cause behind heart failure. Axon Therapies is implementing two double-blinded randomized feasibility studies: one for Heart Failure with Preserved Ejection Fraction (HFpEF) and the other for Heart Failure with Reduced Ejection Fraction (HFrEF).
Co-founder Zoar Engelman, PhD, has been appointed as the new Chief Executive Officer. Engelman expressed optimism regarding the funding, stating, "Heart failure is one of the leading causes of hospitalization and death worldwide, yet patients still face a lack of effective treatment options. Our implant-free, minimally invasive therapy is designed to address a core physiological driver of the disease. This funding positions us to advance to pivotal trials and bring hope to patients who urgently need new solutions."
Splanchnic Ablation Therapy: A New Approach
The company is focusing its efforts on a proprietary method called Splanchnic Ablation for Volume Management (SAVM). This innovative treatment targets overactivity in the sympathetic nervous system, a critical factor that exacerbates heart failure conditions. With the introduction of the Satera™ Ablation System, which employs a non-implant catheter-based approach, Axon Therapies aims to significantly improve patients' quality of life by addressing this particular issue.
Alongside funding and clinical trials, Axon Therapies is making strategic moves to broaden its horizons by establishing a new European headquarters, named Axon Vascular Europe Ltd, in the UK. Engelman indicated that this new base would greatly enhance clinical trial efforts and position the company better in the European heart failure market, which holds substantial growth potential.
Exciting Future Ahead
Dr. John Yianni, a partner at Earlybird Venture Capital, conveyed confidence in the company’s vision, stating, "Our investment in Axon Therapies was driven by a clear vision to address a large unmet clinical need and improve the lives of patients with heart failure. With Dr. Engelman's leadership and the team's groundbreaking technology, we are excited to support Axon as they advance solutions that can make a real difference for patients and their families."
Moreover, Dr. James Eadie, Managing Director at Santé Ventures, noted the significant market potential for Axon’s technology, asserting, "Axon's technology represents a first-in-class solution poised to capture a multi-billion-dollar market, making it a highly attractive asset for any major cardiovascular player."
Conclusion
Heart failure is a global concern with over 64 million cases reported worldwide, contributing to more than 1 million hospitalizations annually in the U.S. alone. Despite ongoing medical advancements, many patients continue to suffer from debilitating symptoms with limited effective therapies available. Axon Therapies, with its leading-edge approach and new funding, aims to change this narrative, promising hope for millions confronting this serious health issue.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.